<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81801</article-id><article-id pub-id-type="doi">10.7554/eLife.81801</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-285988"><name><surname>Flower</surname><given-names>Barnaby</given-names><suffix>Dr</suffix></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2659-544X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286558"><name><surname>Hung</surname><given-names>Le Manh</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286557"><name><surname>Mccabe</surname><given-names>Leanne</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-287026"><name><surname>Ansari</surname><given-names>M Azim</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286561"><name><surname>Le Ngoc</surname><given-names>Chau</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287017"><name><surname>Vo Thi</surname><given-names>Thu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287018"><name><surname>Vu Thi Kim</surname><given-names>Hang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287025"><name><surname>Nguyen Thi Ngoc</surname><given-names>Phuong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286559"><name><surname>Phuong</surname><given-names>Le Thanh</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287024"><name><surname>Quang</surname><given-names>Vo Minh</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287015"><name><surname>Dang Trong</surname><given-names>Thuan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287020"><name><surname>Le Thi</surname><given-names>Thao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287019"><name><surname>Nguyen Bao</surname><given-names>Tran</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287016"><name><surname>Kingsley</surname><given-names>Cherry</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287027"><name><surname>Smith</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-186948"><name><surname>Hoglund</surname><given-names>Richard M</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-124380"><name><surname>Tarning</surname><given-names>Joel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4566-4030</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101437"><name><surname>Kestelyn</surname><given-names>Evelyne</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5728-0918</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287022"><name><surname>Pett</surname><given-names>Sarah L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-234553"><name><surname>van Doorn</surname><given-names>Rogier</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287023"><name><surname>Van Nuil</surname><given-names>Jennifer Ilo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200849"><name><surname>Turner</surname><given-names>Hugo</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-13542"><name><surname>Thwaites</surname><given-names>Guy E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2858-2087</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287014"><name><surname>Barnes</surname><given-names>Eleanor</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-287021"><name><surname>Rahman</surname><given-names>Motiur</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-94984"><name><surname>Walker</surname><given-names>Ann Sarah</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0412-8509</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101433"><name><surname>Day</surname><given-names>Jeremy N</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7843-6280</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101443"><name><surname>Chau</surname><given-names>Nguyen VV</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-222851"><name><surname>Cooke</surname><given-names>Graham S</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><institution>Oxford University Clinical Research Unit</institution>, <addr-line><named-content content-type="city">Ho Chi Minh City</named-content></addr-line>, <country>Viet Nam</country></aff><aff id="aff2"><institution>Hospital for Tropical Diseases</institution>, <addr-line><named-content content-type="city">Ho Chi Minh City</named-content></addr-line>, <country>Viet Nam</country></aff><aff id="aff3"><institution content-type="dept">MRC Clinical Trials Unit</institution>, <institution>University College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff4"><institution content-type="dept">Nuffield Department of Medicine</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution content-type="dept">Department of Infectious Disease</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><institution content-type="dept">Mahidol Oxford Tropical Medicine Research Unit</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff7"><institution content-type="dept">Mahidol-Oxford Tropical Medicine Research Unit</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff8"><institution content-type="dept">MRC Centre for Global Infectious Disease Analysis</institution>, <institution>Imperial College London</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff9"><institution>Hospital for Tropical Diseases</institution>, <addr-line><named-content content-type="city">Ho Chi Minh CIty</named-content></addr-line>, <country>Viet Nam</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-218557"><name><surname>Dahari</surname><given-names>Harel</given-names></name><role>Reviewing editor</role><aff><institution>Loyola University Chicago, Stritch School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>bflower@oucru.org</email> (BF);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>09</day><month>01</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e81801</elocation-id><history><date date-type="received"><day>12</day><month>07</month><year>2022</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, Flower et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Flower et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81801-v1.pdf"/><abstract><p><bold>Background:</bold> WHO has called for research into predictive factors for selecting persons who could be successfully treated with shorter durations of direct acting antiviral (DAA) therapy for Hepatitis C. We evaluated early virological response as a means of shortening treatment and explored host, viral and pharmacokinetic contributors to treatment outcome. </p><p><bold>Methods:</bold> Duration of sofosbuvir and daclatasvir (SOF/DCV) was determined according to day 2 (D2) virologic response for HCV genotype (gt) 1- or 6-infected adults in Vietnam with mild liver disease. Participants received 4- or 8-weeks treatment according to whether D2 HCV RNA was above or below 500 IU/ml (standard duration is 12 weeks). Primary endpoint was sustained virological response (SVR12). Those failing therapy were retreated with 12 weeks SOF/DCV. Host IFNL4 genotype and viral sequencing was performed at baseline, with repeat viral sequencing if virological rebound was observed. Levels of SOF, its inactive metabolite GS-331007 and DCV were measured on day 0 and 28. </p><p><bold>Results:</bold> Of 52 adults enrolled, 34 received 4 weeks SOF/DCV, 17 got 8 weeks and one withdrew. SVR12 was achieved in 21/34 (62%) treated for 4 weeks, and 17/17 (100%) treated for 8 weeks. Overall, 38/51 (75%) were cured with first-line treatment (mean duration 37 days). Despite a high prevalence of putative NS5A-inhibitor resistance associated substitutions (RAS), all first-line treatment failures cured after retreatment (13/13). We found no evidence treatment failure was associated with host IFNL4 genotype, viral subtype, baseline RAS, SOF or DCV levels. </p><p><bold>Conclusions:</bold> Shortened SOF/DCV therapy, with retreatment if needed, reduces DAA use in patients with mild liver disease, while maintaining high cure rates. D2 virologic response alone does not adequately predict SVR12 with 4 weeks treatment. </p><p><bold>Funding:</bold> Funded by the Medical Research Council (grant MR/P025064/1) and The Global Challenges Research Fund (Wellcome Trust Grant 206/296/Z/17/Z).) </p><p><bold>Clinical trial number:</bold> ISRCTN17100273</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/P025064/1</award-id><principal-award-recipient><name><surname>Cooke</surname><given-names>Graham S</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>206/296/Z/17/Z</award-id><principal-award-recipient><name><surname>Cooke</surname><given-names>Graham S</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Leanne Mccabe, has received a grant from the Medical Research Council UK to the MRC Clinical Trials Unit [MC_UU_00004/03]. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf3"><p>Sarah L Pett, has received grants from Gilead Sciences, ViiV Healthcare, Janssen-Cilag, Academy of Medical Sciences, EDCTP, NIHR, NIH, and is a member of the TIPAL (Treating people with idiopathic pulmonary fibrosis with the addition of lansoprazole trial, ISRCTN13526307) DSMB. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf4"><p>Graham S Cooke, is a board member of MHRA. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: In METHODS section we state: Patients referred to the trial were initially enrolled into an observational study which included fibroscan assessment and genotyping. Individuals in this cohort found to be potentially eligible for the trial were invited for further screening. All patients provided written informed consent.In Ethics subsection we state: The trial was approved by the research ethics committees of The Hospital for Tropical Diseases31 (ref: CS/BND/18/25), Vietnam Ministry of Health32 (ref: 6172/QĐ-BYTtnam MoH), Imperial College London33 (ref: 17IC4238), and Oxford University Tropical Research Ethics Committee34 (ref: 43-17). The study's conduct and reporting is fully compliant with the World Medical Association's Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects.35 The trial was registered at ISRCTN, registration number is ISRCTN1710027336.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The study protocol and processed study data have been uploaded to the ISRCTN registry (ISRCTN17100273; https://doi.org/10.1186/ISRCTN17100273). The data are available under unrestricted access. The raw, pseudo-anonymised viral load data is available in Source Data File 1. The virus sequencing dataset has been uploaded to Dryad (https://datadryad.org)  and is available here: doi:10.5061/dryad.x0k6djhnp. All data generated in this study is provided in the main text, appendix 1 and Source Data File 1.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Cooke GS</collab><collab>Day JN</collab><collab>Walker AS</collab></person-group><year iso-8601-date="2022">2022</year><source>A pilot study to assess shortened therapy for hepatitis C infected adults in Vietnam</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/ISRCTN17100273">https://doi.org/10.1186/ISRCTN17100273</ext-link><comment>ISRCTN17100273</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Flower B</collab><collab>Hung L</collab><collab>McCabe L</collab><collab>Ansari M</collab><collab>Ngoc C</collab><collab>Thi T</collab><collab>Thi Kim H</collab><collab>Thi Ngoc P</collab><collab>Phuong L</collab><collab>Quang V</collab><collab>Trong T</collab><collab>Thi T</collab><collab>Bao T</collab><collab>Kingsley C</collab><collab>Smith D</collab><collab>Hoglund R</collab><collab>Tarning J</collab><collab>Kestelyn E</collab><collab>Pett S</collab><collab>van Doorn R</collab><collab>Nuil J</collab><collab>Thwaites G</collab><collab>Barnes E</collab><collab>Rahman M</collab><collab>Walker A</collab><collab>Day J</collab><collab>Vinh Chau N</collab><collab>Cooke G</collab></person-group><year iso-8601-date="2022">2022</year><source>Ultra-short response-guided Hepatitis C treatment with sofosbuvir and daclatasvir: the SEARCH study HCV sequence data</source><ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.5061/dryad.x0k6djhnp">https://dx.doi.org/10.5061/dryad.x0k6djhnp</ext-link><comment>Dryad Digital Repository, doi:10.5061/dryad.x0k6djhnp</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-81801-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>